Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol with Standard of Care in Glioblastoma
NCT03980249Phase 1Withdrawn
- Sponsor
- West Virginia University
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carvedilol in glioblastoma (GBM), sponsored by West Virginia University. Primary endpoints: Overall Survival and Progression-Free Survival. Planned start Sep 2020; status: withdrawn.
02
Drugs
carvedilol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03980249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980249.